PMID-18092346 – KPV Anti-Inflammatory Potential in Murine IBD
Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331.
Quick Reference
| Property | Value |
|---|---|
| PMID | 18092346 |
| DOI | 10.1002/ibd.20334 |
| Year | 2008 |
| Journal | Inflammatory Bowel Diseases |
| Study Type | Animal in vivo |
| Evidence Level | V |
| Sample | Murine models (DSS and TNBS colitis) |
| Peptide(s) Studied | KPV |
Key Findings
- Intraperitoneal administration of KPV significantly reduced clinical and histological signs of colitis in both DSS and TNBS murine models
- KPV treatment decreased pro-inflammatory cytokine levels including TNF-α, IL-1β, and IL-6 in colonic tissue
- Histological scoring showed reduced mucosal damage, less inflammatory cell infiltration, and preserved crypt architecture in KPV-treated animals
- KPV demonstrated dose-dependent anti-inflammatory effects comparable to established IBD therapies in these models
- The tripeptide KPV (Lys-Pro-Val) represents the C-terminal fragment of alpha-MSH responsible for the parent molecule's anti-inflammatory properties
Study Design
Controlled animal study using two established murine colitis models: DSS-induced (chemical epithelial barrier disruption) and TNBS-induced (hapten-driven immune-mediated). KPV was administered intraperitoneally at defined doses. Outcomes included disease activity index scoring, histological inflammation assessment, and quantification of pro-inflammatory cytokines in colonic tissue homogenates.
Limitations
- Intraperitoneal route does not translate directly to clinical oral or subcutaneous administration
- Animal colitis models incompletely replicate human IBD pathophysiology (particularly Crohn's disease transmural inflammation)
- No assessment of long-term safety or chronic dosing effects
- Lack of comparison with standard-of-care IBD medications
Clinical Relevance
This study provides direct preclinical evidence for KPV efficacy in IBD-relevant models, complementing the Dalmasso 2008 PepT1 mechanism study. The demonstrated reduction in key pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) mirrors the therapeutic targets of current biologic IBD treatments. Combined with the PepT1-mediated oral uptake data, these findings build a compelling case for KPV as a potential therapeutic peptide for inflammatory bowel conditions, supporting Ageless Peps oral KPV capsule and BPC-157/KPV blend formulations.
Related
#research #animal-in-vivo #evidence-level-V